Broad media coverage of Pentracor's promising blood wash therapy for COVID-19 patients

Hennigsdorf, 18.05.2021 - Today, the German TV station ZDF reported in detail about the promising CRP apheresis for COVID-19 patients from the medical technology company Pentracor GmbH based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB). At Berlin's Havelhöhe Community Hospital, Pentracor's new therapeutic extracorporeal treatment method is now being used with great success on many severely ill COVID-19 patients.

ZDF reports on CRP apheresis as salvation for COVID-19 patients

18.05.2021

ZDF has reported on CRP apheresis treatment for COVID-19 patients.

At the Klinikum Havelhöhe, the therapy is now used for many severely ill Corona patients - with promising results. Nevertheless, all funding applications for a large clinical trial were unsuccessfully rejected. The trial is needed to make the therapy available to COVID-19 patients throughout Germany.

Forum Sanitas reports about the dark side of CRP

07.05.2021

In the 2nd issue 2021 of Forum Sanitas an article about the dark side of CRP has been published.

The latest findings on the pathological action of CRP are summarized and the potential clinical applications of CRP apheresis in acute myocardial infarction, COVID-19, and other conditions are described.

Promising treatment success in patients with severe COVID-19 courses

Hennigsdorf, 21.04.2021 – Pentracor GmbH, a medical technology company based in Hennigsdorf near Berlin (convertible bond ISIN: DE000A289XB9, WKN: A289XB), active in the dynamically growing healthcare sector, has achieved further promising treatment successes with its CE-certified and patent-protected medical product PentraSorb® CRP in patients with severe COVID-19 courses. For example, the Havelhöhe Community Hospital in Berlin has been using Pentracor's new therapeutic extracorporeal treatment method for severely ill COVID-19 patients for several weeks and has already achieved a significant improvement in the patients' clinical condition after a short period of time.

Clinical trial CRP apheresis after myocardial infarction published

11.03.2021

Results of the first clinical trial of CRP apheresis after acute myocardial infarction (CAMI1) were published in the cardiology journal Frontiers in Cardiovascular Medicine.
"CRP apheresis as anti-inflammatory therapy for acute myocardial infarction: results from the CAMI-1 trial."
The article describes that C-reactive protein substantially triggers myocardial damage after myocardial infarction.